Linoleic acid improves assembly of the CII subunit and CIII2/CIV complex of the mitochondrial oxidative phosphorylation system in heart failure.


Journal

Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464

Informations de publication

Date de publication:
16 10 2019
Historique:
received: 26 05 2019
accepted: 24 09 2019
entrez: 18 10 2019
pubmed: 18 10 2019
medline: 14 7 2020
Statut: epublish

Résumé

Linoleic acid is the major fatty acid moiety of cardiolipin, which is central to the assembly of components involved in mitochondrial oxidative phosphorylation (OXPHOS). Although linoleic acid is an essential nutrient, its excess intake is harmful to health. On the other hand, linoleic acid has been shown to prevent the reduction in cardiolipin content and to improve mitochondrial function in aged rats with spontaneous hypertensive heart failure (HF). In this study, we found that lower dietary intake of linoleic acid in HF patients statistically correlates with greater severity of HF, and we investigated the mechanisms therein involved. HF patients, who were classified as New York Heart Association (NYHA) functional class I (n = 45), II (n = 93), and III (n = 15), were analyzed regarding their dietary intakes of different fatty acids during the one month prior to the study. Then, using a mouse model of HF, we confirmed reduced cardiolipin levels in their cardiac myocytes, and then analyzed the mechanisms by which dietary supplementation of linoleic acid improves cardiac malfunction of mitochondria. The dietary intake of linoleic acid was significantly lower in NYHA III patients, as compared to NYHA II patients. In HF model mice, both CI-based and CII-based OXPHOS activities were affected together with reduced cardiolipin levels. Silencing of CRLS1, which encodes cardiolipin synthetase, in cultured cardiomyocytes phenocopied these events. Feeding HF mice with linoleic acid improved both CI-based and CII-based respiration as well as left ventricular function, together with an increase in cardiolipin levels. However, although assembly of the respirasome (i.e., CI/CIII Dietary supplement of linoleic acid is beneficial for improving cardiac malfunction in HF, but is unable to completely cure HF.

Sections du résumé

BACKGROUND
Linoleic acid is the major fatty acid moiety of cardiolipin, which is central to the assembly of components involved in mitochondrial oxidative phosphorylation (OXPHOS). Although linoleic acid is an essential nutrient, its excess intake is harmful to health. On the other hand, linoleic acid has been shown to prevent the reduction in cardiolipin content and to improve mitochondrial function in aged rats with spontaneous hypertensive heart failure (HF). In this study, we found that lower dietary intake of linoleic acid in HF patients statistically correlates with greater severity of HF, and we investigated the mechanisms therein involved.
METHODS
HF patients, who were classified as New York Heart Association (NYHA) functional class I (n = 45), II (n = 93), and III (n = 15), were analyzed regarding their dietary intakes of different fatty acids during the one month prior to the study. Then, using a mouse model of HF, we confirmed reduced cardiolipin levels in their cardiac myocytes, and then analyzed the mechanisms by which dietary supplementation of linoleic acid improves cardiac malfunction of mitochondria.
RESULTS
The dietary intake of linoleic acid was significantly lower in NYHA III patients, as compared to NYHA II patients. In HF model mice, both CI-based and CII-based OXPHOS activities were affected together with reduced cardiolipin levels. Silencing of CRLS1, which encodes cardiolipin synthetase, in cultured cardiomyocytes phenocopied these events. Feeding HF mice with linoleic acid improved both CI-based and CII-based respiration as well as left ventricular function, together with an increase in cardiolipin levels. However, although assembly of the respirasome (i.e., CI/CIII
CONCLUSIONS
Dietary supplement of linoleic acid is beneficial for improving cardiac malfunction in HF, but is unable to completely cure HF.

Identifiants

pubmed: 31619261
doi: 10.1186/s12964-019-0445-0
pii: 10.1186/s12964-019-0445-0
pmc: PMC6796462
doi:

Substances chimiques

Cardiolipins 0
Protein Subunits 0
Linoleic Acid 9KJL21T0QJ
Electron Transport Complex II EC 1.3.5.1
Electron Transport Complex IV EC 1.9.3.1
Electron Transport Complex III EC 7.1.1.8

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128

Références

Expert Opin Investig Drugs. 2016 Jul;25(7):811-26
pubmed: 27104862
Chem Phys Lipids. 2014 Apr;179:42-8
pubmed: 24220496
Nat Rev Cardiol. 2011 Jan;8(1):30-41
pubmed: 21060326
Biochim Biophys Acta. 2012 Sep;1817(9):1588-96
pubmed: 22575443
Biosci Biotechnol Biochem. 2002 Jan;66(1):141-6
pubmed: 11866096
Am J Cardiol. 2003 May 8;91(9A):41F-50F
pubmed: 12729849
Free Radic Biol Med. 2010 Jul 1;49(1):96-108
pubmed: 20385227
J Biol Chem. 2013 Jan 4;288(1):401-11
pubmed: 23172229
Am J Physiol Heart Circ Physiol. 2015 May 15;308(10):H1237-47
pubmed: 25770243
J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):844-859
pubmed: 30168279
Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1069-77
pubmed: 19617406
Lipids Health Dis. 2019 Feb 14;18(1):53
pubmed: 30764880
Nature. 2016 Oct 20;538(7625):406-410
pubmed: 27595392
Biochim Biophys Acta. 2012 May;1818(5):1309-17
pubmed: 22285120
J Physiol. 2015 Sep 1;593(17):3991-4010
pubmed: 26096709
Circ Res. 2000 Sep 1;87(5):392-8
pubmed: 10969037
J Nutr Health Aging. 2013 Jan;17(1):82-9
pubmed: 23299385
Nat Protoc. 2007;2(2):287-95
pubmed: 17406588
Acta Physiol Scand. 1997 Nov;161(3):345-53
pubmed: 9401587
Biochim Biophys Acta. 2007 Jun;1773(6):1000-6
pubmed: 17509700
Cardiovasc Res. 2016 Sep;111(4):338-47
pubmed: 27450980
Cardiovasc Res. 2012 Jun 1;94(3):460-8
pubmed: 22411972
BMJ. 2013 Feb 04;346:e8707
pubmed: 23386268
Am J Physiol Endocrinol Metab. 2014 Sep 15;307(6):E503-14
pubmed: 25074986
J Am Heart Assoc. 2018 Jan 6;7(1):
pubmed: 29306896
J Mol Cell Cardiol. 2016 Nov;100:43-53
pubmed: 27677939

Auteurs

Satoshi Maekawa (S)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.

Shingo Takada (S)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan. s-takada@hotmail.co.jp.
Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. s-takada@hotmail.co.jp.
Faculty of Lifelong Sport, Department of Sports Education, Hokusho University, Ebetsu, Japan. s-takada@hotmail.co.jp.

Hideo Nambu (H)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.

Takaaki Furihata (T)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.

Naoya Kakutani (N)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.
Research Fellow of the Japan Society for the Promotion of Science, Tokyo, Japan.

Daiki Setoyama (D)

Clinical Laboratories, Kyushu University Hospital, Fukuoka, Japan.

Yasushi Ueyanagi (Y)

Clinical Laboratories, Kyushu University Hospital, Fukuoka, Japan.
Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Dongchon Kang (D)

Clinical Laboratories, Kyushu University Hospital, Fukuoka, Japan.
Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Hisataka Sabe (H)

Department of Molecular Biology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Shintaro Kinugawa (S)

Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH